Ads
related to: newest test for prostate cancer- Patient Resources
Download informative brochures for
patients and caregivers.
- About Us
Understand how a PSMA PET scan may
help with your treatment plan.
- Reimbursement Support
The patient support program
can assist insurance assessment.
- Find An Imaging Site
Locate the nearest imaging site
or contact customer service.
- Patient Resources
Search results
Results from the WOW.Com Content Network
Prostate cancer imaging developed by university researchers has shown “extremely encouraging” results in its first clinical trials. ... The new imaging test begins by injecting a commonly used ...
Researchers found that the test had a 95% sensitivity for prostate cancer of grade group 2 or greater, and 99% for grade group 3 or greater. “It does look impressive and exciting.
To measure the impact of new scans and tests, researchers analysed data from more than 16,000 men referred with suspected prostate cancer in two NHS registries covering 16 hospitals.
n/a Ensembl ENSG00000225937 n/a UniProt n a n/a RefSeq (mRNA) n/a n/a RefSeq (protein) n/a n/a Location (UCSC) Chr 9: 76.69 – 76.86 Mb n/a PubMed search n/a Wikidata View/Edit Human Prostate cancer antigen 3 (PCA3, also referred to as DD3) is a gene that expresses a non-coding RNA. PCA3 is only expressed in human prostate tissue, and the gene is highly overexpressed in prostate cancer ...
Prostate cancer antigen 3 is a urine test that detects the overexpression of the PCA3 gene, an indicator of prostate cancer. [32] [46] [47] [44] ConfirmMDx is performed on tissue taken during a prostate biopsy. The test identifies men with clinically significant prostate cancer who would benefit from further testing and treatment.
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) is a clinical trial investigating treatments for high risk or terminal prostate cancer. Recruitment started in 2005 and ended in 2022; as of January 2020, over 10,000 participants had joined the trial.
Ads
related to: newest test for prostate cancer